Three Game-Changing Breakthroughs in Chronic Pain Treatment Are Making Relief More Accessible

Three revolutionary advances in chronic pain treatment are transforming how the 51.6 million Americans living with chronic pain can find relief. From wireless implants that adapt to your pain levels in real-time to remote therapy programs that work as well as in-person treatment, these breakthroughs are making effective pain management more accessible than ever before.

How Does the New Wireless Pain Implant Work?

Researchers at USC have developed a flexible wireless implant that could eliminate the need for opioids in many chronic pain patients. Unlike traditional spinal cord stimulators that require bulky batteries and invasive surgeries, this ultrasound-induced wireless implantable (UIWI) stimulator is powered by a wearable ultrasound transmitter and uses artificial intelligence to personalize treatment.

The device works through a sophisticated three-step process. First, it continuously monitors brain signals through electroencephalogram (EEG) readings to detect pain levels. Then, a machine learning model based on ResNet-18 neural network technology analyzes these signals with 94.8% accuracy, classifying pain into slight, moderate, or extreme levels. Finally, the system automatically adjusts treatment intensity, creating a closed-loop system that provides real-time, personalized pain management.

"What truly sets this device apart is its wireless, smart and self-adaptive capability for pain management," said Qifa Zhou, professor at USC's Alfred E. Mann Department of Biomedical Engineering. "We believe it offers great potential to replace pharmacological schemes and conventional electrical stimulation approaches."

Can Remote Pain Therapy Really Replace In-Person Treatment?

A major study published in JAMA involving over 2,300 patients with high-impact chronic pain found that remote treatments work just as well as traditional in-person therapy. Researchers at Northwestern University tested two approaches: telehealth coaching sessions and a self-completed online program called painTRAINER, both based on cognitive behavioral therapy (CBT) techniques.

The results were impressive. Both remote programs significantly outperformed usual care in helping patients achieve meaningful pain improvement. While the health coach program showed faster results at three months, by six and 12 months, both approaches delivered similar benefits. The improvements extended beyond just pain relief to include better physical functioning and social role functioning.

"The evidence from this study can help clinical practices justify and move forward with offering remote pain coping skills training," explained Christine Rini, professor of Medical Social Sciences at Northwestern University. "We hope to see that more people with chronic pain will have access to pain coping skills training in the future."

What Makes the New Fibromyalgia Drug Different?

After 15 years without a new fibromyalgia treatment, the FDA approved Tonmya (cyclobenzaprine HCl sublingual tablets) in August 2025. This represents a significant breakthrough for the estimated 2-6.4% of Americans living with fibromyalgia, a condition characterized by widespread pain lasting at least three months.

Tonmya is a sublingual tablet that dissolves under the tongue, providing rapid absorption while bypassing the liver's first-pass metabolism. This design reduces the production of norcyclobenzaprine, a long-lasting active metabolite that can cause lingering side effects with traditional oral cyclobenzaprine formulations.

The approval was based on two major clinical trials, RELIEF and RESILIENT, which demonstrated significant pain reduction compared to placebo. In the RESILIENT trial with 457 participants, patients taking Tonmya experienced an average pain reduction of 1.8 points compared to 1.2 points with placebo. The most common side effects were localized to the mouth area and included:

• Oral numbness: Experienced by 23.4% of patients, typically transient and self-limiting
• Abnormal taste: Reported by 11.3% of users, usually temporary
• Oral tingling: Affected 6.9% of participants, generally mild and short-lived

"The chronic pain of fibromyalgia is debilitating to every aspect of a person's life, including causing sleep disturbance and fatigue," said Sharon Waldrop, founder of the Fibromyalgia Association. "For over 15 years, this community has been underserved and waiting for new treatment options. This approval is a promising step forward and brings renewed hope to millions."

These three breakthroughs represent a fundamental shift in chronic pain management, moving from one-size-fits-all approaches to personalized, accessible treatments that can adapt to individual needs. For the millions of Americans struggling with conditions like arthritis, fibromyalgia, back pain, and neuropathy, these advances offer new hope for effective pain relief without the risks associated with long-term opioid use.